Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Duerwei Capsule is a Traditional Chinese Medicine (TCM) combination product developed by Gansu Duyiwei Biological Pharmaceutical. It is formulated from the extracts of *Lamiophlomis rotata* (Du Yiwei) and *Erigeron breviscapus* (Dengzhanxixin). The capsule is designed to treat acute soft tissue injuries characterized by "blood stasis syndrome," a TCM pattern involving localized pain, swelling, and congestion. The therapeutic effects are attributed to the synergistic action of its components, which provide analgesic, anti-inflammatory, and hemostatic benefits, as well as improvement in local microcirculation. It has undergone Phase 3 clinical testing in China to evaluate its efficacy and safety compared to the standard Du Yiwei Capsule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Duerwei Capsule.